182 related articles for article (PubMed ID: 38233233)
1. Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications.
Du MT; Bergsagel PL; Chesi M
Hematol Oncol Clin North Am; 2024 Apr; 38(2):533-546. PubMed ID: 38233233
[TBL] [Abstract][Full Text] [Related]
2. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
3. Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E; Pandiella A
Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.
Cooke RE; Gherardin NA; Harrison SJ; Quach H; Godfrey DI; Prince M; Koldej R; Ritchie DS
J Transl Med; 2016 Sep; 14(1):259. PubMed ID: 27599546
[TBL] [Abstract][Full Text] [Related]
5. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
7. Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.
Westwood JA; Matthews GM; Shortt J; Faulkner D; Pegram HJ; Duong CP; Chesi M; Bergsagel PL; Sharp LL; Huhn RD; Darcy PK; Johnstone RW; Kershaw MH
Leuk Res; 2014 Aug; 38(8):948-54. PubMed ID: 24934848
[TBL] [Abstract][Full Text] [Related]
8. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
[TBL] [Abstract][Full Text] [Related]
10. Mouse models of human multiple myeloma subgroups.
Winkler W; Farré Díaz C; Blanc E; Napieczynska H; Langner P; Werner M; Walter B; Wollert-Wulf B; Yasuda T; Heuser A; Beule D; Mathas S; Anagnostopoulos I; Rosenwald A; Rajewsky K; Janz M
Proc Natl Acad Sci U S A; 2023 Mar; 120(10):e2219439120. PubMed ID: 36853944
[TBL] [Abstract][Full Text] [Related]
11. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
12. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
[TBL] [Abstract][Full Text] [Related]
13. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
Yang L; Wang H; Kornblau SM; Graber DA; Zhang N; Matthews JA; Wang M; Weber DM; Thomas SK; Shah JJ; Zhang L; Lu G; Zhao M; Muddasani R; Yoo SY; Baggerly KA; Orlowski RZ
Oncogene; 2011 Mar; 30(11):1329-40. PubMed ID: 21057542
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic findings in mouse multiple myeloma and Waldenström's macroglobulinemia.
van den Akker TW; Radl J; Franken-Postma E; Hagemeijer A
Cancer Genet Cytogenet; 1996 Feb; 86(2):156-61. PubMed ID: 8603345
[TBL] [Abstract][Full Text] [Related]
16. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
Li X; Pennisi A; Zhan F; Sawyer JR; Shaughnessy JD; Yaccoby S
Br J Haematol; 2007 Sep; 138(6):802-11. PubMed ID: 17760811
[TBL] [Abstract][Full Text] [Related]
17. The 5TMM series: a useful in vivo mouse model of human multiple myeloma.
Asosingh K; Radl J; Van Riet I; Van Camp B; Vanderkerken K
Hematol J; 2000; 1(5):351-6. PubMed ID: 11920212
[No Abstract] [Full Text] [Related]
18. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
19. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
[TBL] [Abstract][Full Text] [Related]
20. Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.
Bordini J; Bertilaccio MT; Ponzoni M; Fermo I; Chesi M; Bergsagel PL; Camaschella C; Campanella A
Haematologica; 2015 Jun; 100(6):834-841. PubMed ID: 25715406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
